Get Full Government Meeting Transcripts, Videos, & Alerts Forever!
Get email alerts on the Vaccine Adjuvants topic
No spam. Unsubscribe anytime.
FDA: novel vaccine adjuvants demand expanded safety monitoring and CMC justification
Summary
At the FDA workshop, OVRR reviewers urged sponsors of adjuvanted vaccines to submit full CMC data for the adjuvant and adjuvanted formulation, justify added benefit, and include extended safety follow‑up (up to 12 months) and AESI monitoring for novel adjuvants.
Dr. Megan McGuire, a team lead in FDA’s Office of Vaccines Research and Review, told the workshop that vaccine adjuvants are considered constituent materials and must meet standards of purity and justified safety for use in adjuvanted vaccine formulations. ‘‘An adjuvant shall not be introduced into a product unless there's satisfactory evidence that it does not adversely affect the safety and potency of this product,’’ she said, citing 21 CFR 610.15.
McGuire reviewed licensed adjuvants used in U.S. products (examples cited included aluminum salts, AS03, MF59, AS01B/AS01E and CpG classes) and described the regulatory expectations for IND submissions that include novel adjuvants. Sponsors should provide a rationale for adjuvant choice, dosing and antigen:adjuvant ratio, CMC characterization of the adjuvant and the adjuvanted formulation (identity, content, particle‑size/absorption characteristics where relevant), and stability and lot‑release data as available.
Nonclinical and early clinical work should be designed to demonstrate added benefit (enhanced immune response or antigen sparing) and to define a safe immunogenic dose. For nonclinical toxicology, McGuire recommended GLP‑compliant studies where appropriate and emphasized use of pharmacology models where the antigen/adjuvant combination is active.
For clinical safety monitoring, FDA reviewers said sponsors should plan active solicited adverse event surveillance and extended follow‑up when a novel adjuvant is used. McGuire noted that novel adjuvants often trigger requests for up to 12 months of safety follow‑up for serious adverse events, deaths, new‑onset medical conditions and adverse events of special interest—particularly immune‑mediated and neuroinflammatory events. The agency advised use of standardized MedDRA terms and robust monitoring and reporting plans.
During Q&A, participants asked about multiple‑adjuvant formulations, lipid nanoparticle classification (FDA does not currently treat LNPs as adjuvants), minimum safety database size (McGuire indicated several thousand subjects may be expected for phase‑3 safety assurance depending on product), and opportunities to consult with FDA through pre‑IND interactions.
Sponsors developing adjuvanted vaccines should document CMC characterization of both adjuvant and adjuvanted product, demonstrate added benefit with nonclinical or early clinical data where feasible, and align safety monitoring plans with FDA guidance and expected durations for novel adjuvants.
